Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan.
Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Thorac Cancer. 2024 Jan;15(2):131-141. doi: 10.1111/1759-7714.15169. Epub 2023 Nov 28.
Molecular abnormalities in the Wnt/β-catenin pathway confer malignant phenotypes in lung cancer. Previously, we identified the association of leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6) with oncogenic Wnt signaling, and its downregulation upon β-catenin knockdown in non-small cell lung cancer (NSCLC) cells carrying CTNNB1 mutations. The aim of this study was to explore the mechanisms underlying this association and the accompanying phenotypes.
LGR6 expression in lung cancer cell lines and surgical specimens was analyzed using quantitative RT-PCR and immunohistochemistry. Cell growth was assessed using colony formation assay. Additionally, mRNA sequencing was performed to compare the expression profiles of cells subjected to different treatments.
LGR6 was overexpressed in small cell lung cancer (SCLC) and NSCLC cell lines, including the CTNNB1-mutated NSCLC cell lines HCC15 and A427. In both cell lines, LGR6 knockdown inhibited cell growth. LGR6 expression was upregulated in spheroids compared to adherent cultures of A427 cells, suggesting that LGR6 participates in the acquisition of cancer stem cell properties. Immunohistochemical analysis of lung cancer specimens revealed that the LGR6 protein was predominantly overexpressed in SCLCs, large cell neuroendocrine carcinomas, and lung adenocarcinomas, wherein LGR6 overexpression was associated with vascular invasion, the wild-type EGFR genotype, and an unfavorable prognosis. Integrated mRNA sequencing analysis of HCC15 and A427 cells with or without LGR6 knockdown revealed LGR6-related pathways and genes associated with cancer development and stemness properties.
Our findings highlight the oncogenic roles of LGR6 overexpression induced by aberrant Wnt/β-catenin signaling in lung cancer.
Wnt/β-连环蛋白通路中的分子异常赋予肺癌恶性表型。先前,我们发现富含亮氨酸重复的 G 蛋白偶联受体 6(LGR6)与致癌性 Wnt 信号有关,并且在携带 CTNNB1 突变的非小细胞肺癌(NSCLC)细胞中β-连环蛋白敲低时其表达下调。本研究旨在探讨这种关联及其伴随表型的潜在机制。
采用定量 RT-PCR 和免疫组织化学法分析肺癌细胞系和手术标本中的 LGR6 表达。采用集落形成实验评估细胞生长。此外,进行 mRNA 测序以比较不同处理组细胞的表达谱。
LGR6 在小细胞肺癌(SCLC)和 NSCLC 细胞系中过表达,包括 CTNNB1 突变的 NSCLC 细胞系 HCC15 和 A427。在这两种细胞系中,LGR6 敲低均抑制细胞生长。与 A427 细胞的贴壁培养相比,球体中的 LGR6 表达上调,表明 LGR6 参与获得癌症干细胞特性。对肺癌标本的免疫组织化学分析表明,LGR6 蛋白主要在 SCLC、大细胞神经内分泌癌和肺腺癌中过表达,其中 LGR6 过表达与血管侵犯、野生型 EGFR 基因型和不良预后相关。对 HCC15 和 A427 细胞进行 LGR6 敲低或不敲低的整合 mRNA 测序分析,揭示了与癌症发展和干细胞特性相关的 LGR6 相关途径和基因。
我们的研究结果强调了异常 Wnt/β-连环蛋白信号诱导的 LGR6 过表达在肺癌中的致癌作用。